Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients

  • Authors:
    • Alessio Provenzani
    • Monica Notarbartolo
    • Manuela Labbozzetta
    • Paola Poma
    • Giovanni Vizzini
    • Paola Salis
    • Chiara Caccamo
    • Tullio Bertani
    • Ugo Palazzo
    • Piera Polidori
    • Bruno Gridelli
    • Natale D'Alessandro
  • View Affiliations

  • Published online on: September 12, 2011     https://doi.org/10.3892/ijmm.2011.794
  • Pages: 1093-1102
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tacrolimus is a substrate of cytochrome P4503A (CYP3A) enzymes as well as of the drug transporter ABCB1. We have investigated the possible influence of CYP3A5 and ABCB1 single nucleotide polymorphisms (SNPs) and other factors (e.g. albumin, hematocrit and steroids) on tacrolimus blood levels achieved in a population of Caucasian liver (n=51) and kidney (n=50) transplant recipients. At 1, 3 and 6 months after transplantation, tacrolimus doses (mg/kg/day) and trough blood levels (C0) were recorded and the weight-adjusted tacrolimus dosage (mg/kg/day) was calculated. Polymerase chain reaction followed by restriction fragment length polymorphism analysis was used for genotyping CYP3A5*1 and *3 [6986A>G] as well as ABCB1 at exons 21 [2677G>T/A] and 26 [3435C>T] in both liver transplant donors and recipients and in kidney transplant recipients. Of the 152 subjects studied, 84.9% showed a CYP3A5*3/*3 genotype. The total frequency of the allelic variant *3 was 93%. For the G2677T/A and C3435T polymorphisms the total frequencies of the allelic variants T/A and T were 44.7 and 46.7%, respectively. At 1, 3 and 6 months after transplantation the dose-adjusted C0 levels were significantly lower in patients with one copy of the *1 allele compared to those homozygous for the *3 allele. In the case of liver transplant patients the tacrolimus dose requirements were dominantly influenced by the polymorphisms of the CYP3A5 gene in the donors. With regard to the ABCB1 SNPs, in general they did not show any appreciable influence on tacrolimus dosing requirements; however, kidney transplant recipients carrying the 2677T/A allele required significantly higher daily tacrolimus doses than subjects homozygous for the wild-type allele. Identification of CYP3A5 single nucleotide polymorphisms prior to transplantation could contribute to evaluate the appropriate initial dosage of tacrolimus in the patients.

Related Articles

Journal Cover

December 2011
Volume 28 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Polidori P, et al: Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med 28: 1093-1102, 2011.
APA
Provenzani, A., Notarbartolo, M., Labbozzetta, M., Poma, P., Vizzini, G., Salis, P. ... D'Alessandro, N. (2011). Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. International Journal of Molecular Medicine, 28, 1093-1102. https://doi.org/10.3892/ijmm.2011.794
MLA
Provenzani, A., Notarbartolo, M., Labbozzetta, M., Poma, P., Vizzini, G., Salis, P., Caccamo, C., Bertani, T., Palazzo, U., Polidori, P., Gridelli, B., D'Alessandro, N."Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients". International Journal of Molecular Medicine 28.6 (2011): 1093-1102.
Chicago
Provenzani, A., Notarbartolo, M., Labbozzetta, M., Poma, P., Vizzini, G., Salis, P., Caccamo, C., Bertani, T., Palazzo, U., Polidori, P., Gridelli, B., D'Alessandro, N."Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients". International Journal of Molecular Medicine 28, no. 6 (2011): 1093-1102. https://doi.org/10.3892/ijmm.2011.794